Dr Min Yeo

29/08/2026

21/08/2026

Now online! Gut microbiota generate dinitrosyl iron complexes with cardiometabolic benefits: Gut bacteria convert inorganic nitrate and non-heme iron into bioactive dinitrosyl iron complexes (DNICs) that distribute systemically and signal independently of free nitric oxide. These microbe-derived DNICs protect against cardiometabolic disease and fatty liver by restoring compromised metabolic signaling pathways.

http://dlvr.it/TV5zmJ

21/08/2026

One to add to my reading list

11/08/2026

Seemingly false-positive antinuclear antibody (ANA) tests are common, but high-titer ANAs may be associated with chronic liver disease, a new study reveals.

"This association makes sense: Immune dysregulation is a feature of not only autoimmune hepatitis, but also chronic liver disease generally," writes Allan S. Brett, MD.

11/08/2026

Nature Reviews Endocrinology: This Review highlights adipose humoral and neuronal pathways that operate through inter-organ communication to regulate systemic metabolism, examines how physiological and pathological contexts shape these signals, and explores emerging technologies and translational opportunities for targeting adipose networks in metabolic disease.

Link to the Review in the comments.

07/08/2026

06/08/2026

The findings of a study in Nature Health show how birth order can affect human disease. First-borns carry excess risk for neurodevelopmental conditions and immune-allergic diseases while second-borns carry excess risk for substance abuse and gastrointestinal conditions.

Link to the research in the comments.

04/08/2026

Continuous monitoring (CGM), initially recommended primarily for people with type 1 , has rapidly expanded to patients with type 2 diabetes and, more recently, even to individuals without diabetes. This broadening use underscores the importance of critically examining the evidence supporting CGM across populations, clarifying where benefits are established, where they are modest, and where they remain uncertain.

This review examines the evidence for CGM use beyond type 1 diabetes or , explores its usefulness as a behavior change aid, and critically assesses its expanding role in the care of people with dysglycemia. https://ja.ma/4pHaS6i